Login to Your Account



Boston Biomedical Morphs Deal Into $2.6B Dainippon Buyout

By Trista Morrison
Staff Writer

Thursday, March 1, 2012

Less than a year after picking up several regional options to Boston Biomedical Inc.'s lead cancer stem cell drug BBI608, Dainippon Sumitomo Pharma Co. Ltd. skipped exercising those options in favor of an all-out acquisition.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription